BaroSense’s minimally invasive surgical instruments are targeted towards the weight loss market. This is an enormous market as it is estimated that more than 300 million people suffer from obesity worldwide. Obesity has reached epidemic proportions in the United States, affecting approximately 60 million adults. Estimates are that more than 300,000 deaths a year occur in the United States due to obesity related diseases.
BaroSense’s Trans-oral Endoscopic Restrictive Implant System (TERIS) consists of taking the outside part of stomach, turning it inside out and then stapling it. Anchors are placed and restrictors are inserted. The result these procedures is that the size and function of the stomach is altered resulting in patients feeling both early meal satiation and prolonged satiety.
This general anesthesia procedure should take between 45 minutes and 90 minutes, depending on the level of the physician’s familiarity with TERIS. In most cases, patients are discharged from the hospital the day of the procedure or one day later. The staples are designed to be life-long, eliminating the need for a follow-up procedure to remove the staples.
In BaroSense’s clinical studies, patients lose an average of 30% to 40% of their excess weight after one-year. No side effects have been detected thus far in clinical trials.Minimally Invasive Weight Loss Surgery,